Josh Brown on Insmed, Gilead, and Biotech Sector Opportunities

Insmed: A Biotech Surprise

• 💡 Insmed (INSM) is highlighted as a significant recent winner in the biotech sector, up approximately 95% over the last 3 months.
• 📌 While not a current buy recommendation, Insmed serves as an example of a large winner that can unexpectedly emerge.

Gilead Sciences: A Strong Contender

• 🚀 Gilead Sciences is presented as the third biotech name on Josh Brown's 'Best Stocks' list, following Insmed and Alnylam.
• 🎯 The company is recognized as the world leader in HIV treatment and prevention.
• ✅ Gilead recently had an excellent earnings call, a rarity in the pharmaceutical space, with strong gross margin improvements and a promising new drug whose prescriptions were written within hours of approval.
• 📈 Traders can use 110 for risk management, while investors should monitor the 200-day moving average (currently around 102), which the stock has stayed above for 12 consecutive months.
• 🔍 The stock is believed to be under accumulation, with a potential trigger for further upside if it breaks 120.

Biotech Sector Outlook

• 📊 The biotech sector is showing signs of turning a corner after a difficult period, with Insmed being one of the first to make a significant move.
• 📈 Healthcare, including pharma and biotech, can serve as growth engines within the broader market, especially if investors rotate out of other popular growth names.
• ⚠️ Despite being